Document:

Exhiit 10.6

 

[EXECUTION COPY]

 

FIRST AMENDMENT

 

This FIRST AMENDMENT, dated as of June 24, 2005
(this “Amendment Agreement”), is among WEIGHT WATCHERS INTERNATIONAL,
INC., a Virginia corporation (the “Borrower”) and certain of the Lenders
(such capitalized term, and other terms used in this Amendment Agreement, to
have the meanings set forth in Part I below).

 

W I T N E S S E T H:

 

WHEREAS, the Borrower, the various financial
institutions party thereto, Credit Suisse, acting through its Cayman Islands
Branch, as the syndication agent and as a lead arranger, and The Bank of Nova
Scotia, as (x) the administrative agent for the Lenders, and (y) a lead
arranger for the Lenders are party to the Fifth Amended and Restated Credit
Agreement, dated as of January 21, 2004 (as further amended, supplemented
or otherwise modified prior to the First Amendment Effective Date, the “Existing
Credit Agreement”);

 

WHEREAS, the Borrower has requested that the Lenders
amend certain provisions of the Existing Credit Agreement as herein provided;
and

 

WHEREAS, the Lenders have agreed, subject to the terms
and conditions set forth below, to amend the Existing Credit Agreement as more
specifically set forth herein (the Existing Credit Agreement, as amended by
this Amendment, being referred to as the “Credit Agreement”);

 

NOW, THEREFORE, in consideration of the premises and
the mutual agreements herein contained, the parties hereto hereby agree as
follows.

 

PART I

DEFINITIONS

 

SUBPART 1.1.  Certain Definitions.  The following terms (whether or not
underscored) when used in this Amendment Agreement shall have the following
meanings (such meanings to be equally applicable to the singular and plural
form thereof):

 

“Amendment Agreement” is defined in
the preamble.

 

“Borrower” is defined in the preamble.

 

“Credit Agreement” is defined in the third
recital.

 

“Existing Credit Agreement” is defined in the first
recital.

 

“First Amendment Effective Date” is
defined in Subpart 3.1.

 

 

SUBPART 1.2.  Other Definitions.  Terms for which meanings are provided in the
Credit Agreement are, unless otherwise defined herein or the context otherwise
requires, used in this Amendment Agreement with such meanings.

 

PART II

AMENDMENT AND RESTATEMENT OF THE

CREDIT AGREEMENT

 

SUBPART 2.1.  Amendment to Article I.  Article I of the Existing Credit
Agreement is hereby amended in accordance with Subparts 2.1.1 and 2.1.2.

 

SUBPART 2.1.1.  Section 1.1 of the Existing Credit
Agreement is hereby amended by inserting the following definitions in the
appropriate alphabetical order:

 

“First
Amendment Effective Date” is defined in Subpart 3.1 of the First Amendment,
dated as of June 24, 2005, among the Borrower and the Lenders party
thereto.

 

“Redemption”
means the redemption by WW.com of all of the Capital Securities of WW.com owned
by ARTAL.

 

“Redemption
Debt” means the Indebtedness incurred by WW.com and its Subsidiaries to
fund the Redemption as such Indebtedness may be Refinanced from time to time.

 

“WW.com”
means WeightWatchers.com, Inc. a Delaware corporation.

 

“Target Date”
means January 31, 2007.

 

SUBPART 2.1.2.  The following definitions set forth in Section 1.1
of the Existing Credit Agreement are modified as follows:

 

(a)           “Debt”
is amended by inserting the following proviso at the end of such definition
prior to the “.” at the end thereof:

 

provided
that Indebtedness of WW.com and its Subsidiaries shall only be included as Debt
if either: (x) the Target Date has occurred but the Redemption has not occurred
or (y) the Redemption has occurred and the Redemption Debt is no longer
outstanding

 

(b)           “Interest
Expense” is amended by inserting the following proviso at the end of such
definition prior to the “.” at the end thereof:

 

provided
that interest expense of WW.com and its Subsidiaries shall only be included as
Interest Expense if either: (x) the Target Date has occurred but the 

 

2

 

Redemption
has not occurred or (y) the Redemption has occurred and the Redemption Debt is
no longer outstanding.

 

(c)           “Net
Income” is amended by inserting the following proviso at the end of such
definition prior to the “.” at the end thereof:

 

provided
that net income of WW.com and its Subsidiaries shall only be included as Net
Income if either: (x) the Target Date has occurred but the Redemption has not
occurred or (y) the Redemption has occurred and the Redemption Debt is no
longer outstanding

 

SUBPART 2.2.  Amendments to Article VII.  Article VII of the Existing Credit
Agreement is hereby amended in accordance with Subparts 2.2.1 through 2.2.10.

 

SUBPART 2.2.1.  Section 7.1.4 of the Existing Credit
Agreement is hereby amended by inserting the parenthetical “(other than those
with respect to WW.com and its Subsidiaries so long as WW.com and its
Subsidiaries are not required to be Guarantors hereunder)” after the word “Section”
in the last sentence of such Section.

 

SUBPART 2.2.2.  Section 7.1.8 of the Existing Credit
Agreement is hereby amended by inserting the parenthetical “(other than WW.com
and its Subsidiaries so long as WW.com and its Subsidiaries are not required to
be Guarantors hereunder)” after the words “U.S. Subsidiary” each time they
appear in such Section.

 

SUBPART 2.2.3.Clause
(a) of Section 7.1.7 of the Existing Credit Agreement is hereby
amended by inserting the following proviso immediately after the phrase “as the
case may be” but prior to the “; and” at the end of such clause:

 

provided,
however, that WW.com and its U.S. Subsidiaries shall only be required to
execute a supplement to the Subsidiary Guaranty, a supplement to the WWI
Security Agreement and a Mortgage, if either: (x) the Target Date has occurred
but the Redemption has not occurred or (y) the Redemption has occurred and the
Redemption Debt is no longer outstanding

 

SUBPART 2.2.4.  Clause (b) of Section 7.1.7 of the
Existing Credit Agreement is hereby amended by inserting the following proviso
immediately after the phrase “as the Administrative Agent may reasonably
require” but prior to the “.” at the end of such clause:

 

and provided, further, that the
Borrower and WW.com and its U.S. Subsidiaries shall only be required to pledge
the Capital Securities of WW.com and its Subsidiaries, as applicable, if
either: (x) the Target Date has occurred but the Redemption has not occurred or
(y) the Redemption has occurred and the Redemption Debt is no longer
outstanding

 

SUBPART 2.2.5.  Section 7.2.2 of the Existing Credit
Agreement is hereby amended by deleting the word “and” from the end of clause
(j) thereof, inserting the word “and” at the end of clause (k) thereof and inserting
the following new clause (l) immediately after clause (k) thereof:

 

3

 

(l)  Redemption Debt in an amount not to exceed
$250,000,000;

 

SUBPART 2.2.6.  Section 7.2.3 of the Existing Credit
Agreement is hereby amended by deleting the word “and” from the end of clause
(j) thereof, and inserting new clauses (l) and (m) immediately after clause (k)
thereof:

 

(l)  Liens granted by WW.com to secure payment of
Indebtedness of the type permitted and described in clause (l) of Section 7.2.2;
and

 

(m)  Liens on Capital Securities of WW.com granted
by the Borrower to secure payment of Indebtedness of the type permitted and
described in clause (l) of Section 7.2.2.

 

SUBPART 2.2.7.  Section 7.2.5 of the Existing Credit
Agreement is hereby amended by deleting the word “and” from the end of clause
(m) thereof and inserting the following new clauses (o) and (p) immediately
after clause (n) thereof:

 

(o)  other Investments made by the Borrower
consisting of the exercise of warrants to purchase Capital Securities of WW.com
and the purchase of Capital Securities of WW.com from any Person other than
ARTAL in an amount not to exceed $150,000,000; and

 

(p)  at any time WW.com and its U.S. Subsidiaries
are not required to be Guarantors, other Investments made by WW.com and its
Subsidiaries;

 

SUBPART 2.2.8.  Section 7.2.9 of the Existing Credit
Agreement is hereby amended by deleting the word “or” from the end of clause (b) thereof,
replacing the “.” at the end of clause (c) thereof with “; or” and
inserting the following new clause (d) immediately after clause (c) thereof:

 

(d)  at
any time WW.com and its U.S. Subsidiaries are not required to be Guarantors,
Dispositions made by WW.com and its Subsidiaries;

 

SUBPART 2.2.9.  Section 7.2.11 of the Existing Credit
Agreement is hereby amended by deleting the word “and” at the end of clause (a) thereof,
replacing the “.” at the end of clause (b) thereof with “; and” and
inserting the following new clause (c) immediately after clause (b) thereof:

 

(c) 
except that WW.com may consummate the Redemption.

 

4

 

SUBPART 2.2.10.  Section 7.2.12 of the Existing Credit
Agreement is hereby amended by replacing the word “or” at the end of clause (iv) in
the parenthetical in the first sentence thereof with a “,”, and inserting the
following new clause (vi) immediately after clause (v) thereof:

 

or (vi) in the case of (a)(i) and (b), any
restrictions with respect to WW.com imposed pursuant to the loan agreement
entered into in respect of the Redemption Debt

 

PART III

CONDITIONS TO EFFECTIVENESS

 

SUBPART 3.1.  Effective Date.  This Amendment Agreement shall become
effective on the date (the “First Amendment Effective Date”) when all of
the conditions set forth in this Part have been satisfied.

 

SUBPART 3.1.1.  Execution of Counterparts.  The Administrative Agent shall have received
counterparts of this Amendment, duly executed and delivered on behalf of the
Borrower and the Required Lenders.

 

SUBPART 3.1.2.  Satisfactory Legal Form.  All documents executed or submitted pursuant
hereto by or on behalf of the Borrower shall be reasonably satisfactory in form
and substance to the Administrative Agent and its counsel, and the
Administrative Agent and its counsel shall have received all information,
approvals, documents or instruments as the Administrative Agent or such counsel
may reasonably request.

 

PART IV

REPRESENTATIONS AND WARRANTIES

 

To induce the Lenders to enter into this Amendment
Agreement, the Borrower represents and warrants to the Lenders as set forth
below.

 

SUBPART 4.1.  Validity, etc.  This Amendment Agreement constitutes the
legal, valid and binding obligation of each Borrower enforceable in accordance
with its terms subject to the effects of bankruptcy, insolvency, fraudulent
conveyance, reorganization, moratorium and other similar laws relating to or
affecting creditors’ rights generally, general equitable principles (whether
considered in a proceeding in equity or at law) and an implied covenant of good
faith and fair dealing.

 

SUBPART 4.2.  Representations and Warranties, etc.  Both before and after giving effect to this
Amendment Agreement, the statements set forth in Section 5.2.1 of the
Credit Agreement are true and correct.

 

5

 

PART V

MISCELLANEOUS

 

SUBPART 5.1.  Cross-References.  References in this Amendment Agreement to any
Part or Subpart are, unless otherwise specified or otherwise required by
the context, to such Part or Subpart of this Amendment Agreement.

 

SUBPART 5.2.  Loan Document Pursuant to Existing Credit
Agreement.  This Amendment Agreement
is a Loan Document executed pursuant to the Existing Credit Agreement and shall
be construed, administered and applied in accordance with all of the terms and
provisions of the Existing Credit Agreement and, after the First Amendment
Effective Date, the Credit Agreement.

 

SUBPART 5.3.  Successors and Assigns.  This Amendment Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective
successors and assigns.

 

SUBPART 5.4.  Counterparts.  This Amendment Agreement may be executed by
the parties hereto in several counterparts, each of which when executed and
delivered shall be deemed to be an original and all of which together shall
constitute but one and the same agreement. 
Delivery of an executed counterpart of a signature page to this
Amendment Agreement by facsimile shall be effective as delivery of a manually
executed counterpart of this Amendment Agreement.

 

SUBPART 5.5.  Governing Law.  THIS AMENDMENT AGREEMENT SHALL BE GOVERNED BY
AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK
(INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE
GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).

 

SUBPART 5.6.  Release.  Upon the consummation of the Redemption and
the incurrence of the Redemption Debt, the Lenders hereby release any Lien they
have or the Administrative Agent has on any Capital Securities of WW.com owned
by the Borrower on the date hereof until such time, if ever, as the Borrower is
required to grant and perfect a Lien on such Capital Securities to the
Administrative Agent for the benefit of the Lenders pursuant to the terms of
the Credit Agreement.

 

6

 

IN WITNESS WHEREOF, the parties hereto have caused
this Amendment Agreement to be executed by their respective officers thereunto
duly authorized as of the date first above written.

 

	
   

  	
  WEIGHT WATCHERS INTERNATIONAL, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
    /s/
  Linda Huett

  	
   

  
	
   

  	
   

  	
  Name: 
  Linda Huett

  
	
   

  	
   

  	
  Title: 
  President and Chief Executive Officer

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  [INSERT NAME OF LENDER]

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  
						

 

7Exhibit 10.1

 

Modification to CRADA No. 26-97

July 2005

 

Modification
to CRADA No. 26-97

July 15,
2005

 

Appendix A

 

The following research objectives are added to those described in
Appendix A of CRADA No. 26-97.

 

A.                                    Targeting
of Interleukin-13 Receptor for pediatric brain tumor therapy:  In contrast to malignant glioma in adults
that are predominantly supratentorial, pediatric tumors are also localized in
posterior fossa and brain stem.  Because
of their location, Neurosurgcons are unable to resect most of the tumor
resulting in progressive disease with poor prognosis.  As there is not much option available for
these children, an urgent search for innovative therapeutic measures is needed.  Recent studies have demonstrated that 83% of
36 different pediatric brain tumor samples express IL-13R2 chain when
analyzed by immunohistochemical and in-situ hybridization studies (Kawakami et
al. Cancer 2004).  Although both assays
produced compatible results, quantitative difference in receptor density
between various samples is not known.  In
addition, it is not known whether IL-13 receptors in pediatric brain tumors are
sensitive to cytotoxic effect of IL-13-PE as adult glioma in vitro. 
Furthermore, it is not known whether IL-13-PE will be efficacious in
these tumors in animal models of brain tumors in
vivo.  Previous studies have
suggested that glioma cells expressing IL-13R are highly sensitive to IL-13-PE.  As IL-13R-targeted cytotoxin [IL13-PE38QQR]
is being tested in PRECISE Phase 3 clinical trial in adult patients with
recurrent glioma, it will be of importance to study IL-13-PE in not only in vitro and in vivo animal studies of pediatric brain tumors but also
tested in patients to address unmet medical need and to unravel antitumor
activity of this important molecule.

 

The following studies are planned to address important issues
identified above:

 

1.                                       Analysis of IL-13 receptor expression and type of
receptors in additional patient derived samples.  Previous study utilized limited number of
pediatric tumor samples including glioma, low-grade astrocytoma, giant cell
tumor, mixed glioma and ganglioglioma. 
Additional tumor samples will be acquired from Cooperative Human Tissue
Network (CHTN).  FDA IRB (RIHSC) has
approved our request.

 

2.                                       Identification on pediatric brain tumor cell lines and
isolation of primary cell cultures of tumors.  Tumor cell lines derived from pediatric
glioma, low-grade astrocytoma, giant cell tumor, mixed glioma and ganglioglioma
will be obtained from Commercial source or from investigators.  In addition, primary cell cultures from
surgical samples will be generated. 
These cells and cell lines will be tested for the expression of IL-13R
and sensitivity to IL-13-PE in vitro by
various techniques established in our laboratories.

 

1

 

3.                                       Efficacy of IL-13-PE in Pediatric brain tumor models:  The efficacy of IL-13PE will be evaluated in
tumor bearing mice.  Tumor cell lines
derived from various tumors will be established as tumors in immunodeficient
mice.  These animals will be then treated
with IL-13-PE by various routes and schedules. 
Initially, animals with subcutaneous flank tumors will be treated and
later intracranial tumor models will be treated.  Various routes of administration of IL-13-PE
including CED through a burr hole will be evaluated.  Tumor shrinkage, response rate, and animal
survival will be analyzed.

 

These studies
will provide scientific support for a pediatric brain tumor study or tumors in
addition to malignant glioma.

 

B.                                    Evaluation
of synergistic therapeutic efficacy of IL-13-PE with radiation therapy or with
temozolamide:

 

Since radiation induced tumor cell stasis/death and IL-13-PE induced
cell death involve different mechanisms, it is possible that the combination of
radiation and IL-13-PE therapy may lead to combined or synergistic effect on
glioma cells.  As IL-13-PE is being
studied in initially diagnosed glioma along with radiation therapy to support
development, additional in vitro and animal studies should be performed to
determine the optimal schedule of therapy with these two modalities.  Similarly, since temozolomide (approved for
glioma therapy) and IL-13-PE will mediate therapeutic effect through different
mechanisms, it is also possible that the combination of both drugs may mediate
combined or synergistic effects.

 

Planned
studies include:

 

1.                                       In
vitro sublethal irradiation of glioma cell lines followed by culture with IL-13-PE
and conversely incubation with IL-13-PE followed by irradiation will be
performed and the growth, cell viability and cytotoxicity to IL-13-PE will be
assessed.  These studies have already
completed and the results show that prior irradiation although increase IL-13Ralpha2
mRNA expression but it did not enhance sensitivity to IL-13-PE.  Similarly, prior treatment with IL-13-PE did
not enhance sensitivity to irradiation.

 

2.                                       Concomitant
radiation and IL-13-PE incubation will also be performed in vitro and cell growth and protein
synthesis will be assessed.  Preliminary
studies indicate that the combined radiation and IL-13-PE incubation mediates
enhanced antitumor effect in vitro when compared to either modality alone.  Confirmatory studies are being performed and
need continued support to complete these studies, which are expected to be completed
by the end of the second quarter of 2005.

 

3.                                       Pre-treatment
irradiation of subcutaneous or intracranial glioma tumors followed by local
delivery of IL-13-PE are also planned that will be initiated in the beginning
of 2005 and expected to be completed by the end of third quarter of 2005.

 

2

 

4.                                       Concomitant
effect of temozolomide and IL-13-PE in various glioma cell lines in vitro and
the effect of co-administration of temozolomide and IL-13-PE by various routes
in subcutaneous and intracranial tumors will continued to be evaluated.  Preliminary results suggest that temozolomide
synergies with IL-13-PE in mediating antitumor activity in vitro and in
vivo.  These studies are also expected to
be completed in 2005.

 

The following studies began in 2004 and are currently ongoing.  However, if funds remain at the level
proposed in Appendix C Revised. 2, they will not be completed in the year 2005.

 

3.                                      Study
of the mechanism of action of delayed effect of IL-13-PE in normal brain:

 

Clinical studies have demonstrated that IL-13-PE can induce cytotoxic
effect on tumors when administered intratumorally.  In addition, intra-parenchyma administration
of IL-13-PE in normal brain with infiltrating glioma is very well tolerated up
to the dosage of 0.5 microgram/ml.  At
1.0 microgram/ml dose limiting local toxicity has been observed.  In addition, in several patients appearance
of abnormal hyperintense signal on FLAIR images and new gadolinium enhancing
solid lesion with central hypointense area suggesting necrosis in normal or
infiltrated brain parenchyma have been observed between 4 and 8 weeks following
treatment.  This type of phenomenon has
not been observed previously as in all studies most rats or mice were
sacrificed only several days after IL-13-PE infusion.  No long term monitoring was performed after
intraparenchymal administration of IL-13-PE. 
The following studies have been initiated that are expected to lead to
an understanding of the mechanism of this effect and develop strategies to
avoid this delayed effect of IL-13-PE.

 

Planned studies:

 

a.                                       Develop
animal model in mice and rats to simulate human clinical situation by intra
parenchymal administration of IL-13-PE.  Part of
this study is completed and a manuscript has been accepted for publication
(Kawakami et al. J. Neurosurgery, December 2004).

 

b.                                      Study
of brain tissue sections by histology and immunohistochemisty harvested at
various time points of IL-13-PE administration. 
Part of this study has also completed and described in a manuscript
accepted for publication (Kawakami et al. J. Neurosurgery, December 2004).

 

c.                                       Identification
of local or systemic immune mechanism (if any) post IL-13-PE administration in
normal brain.  In some cases, animals
will be immunosuppressed by whole body sub lethal irradiation to determine the
role of chemotherapy on this process in the clinic.  These studies are yet to be initialed and
expected to begin in first quarter 2005.

 

3

 

d.                                      Identification
of the role of cytokines or other factors in this mechanism will be evaluated
by microarray technology, which is available at CBER.

 

4

 

Appendix
C-Revised.2

 

Financial and Staffing Contribution of the Parties:

 

This “Appendix C-Revised.2” replaces in full “Appendix C”, “Appendix
C-Revised” and “Appendix-C-Revised.1” that were attached to the FDA CRADA No. 26-97
entered into by FDA and NeoPharm, Inc. 
This Appendix C-Revised.2” will become effective upon signing below by
representatives of both FDA and NeoPharm, Inc.

 

Collaborator’s Contribution.

 

NeoPharm, Inc. will provide funding agreed upon in this “Appendix
C-Revised.2” at the level of $130,000. 
The term of CRADA No. 26-97 is hereby extended through April 30,
2006.

 

The funds will be used to recruit research personnel, purchase
equipment, laboratory supplies, animals, and reagents.  The PI will recruit one research fellow for
full-time participation in the CRADA project.

 

FDA will use the funds provided by NeoPharm for:

 

	
  Personnel:

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  One
  Post-Doctoral Research Fellow (including overhead charges)

  	
   

  	
  $

  	
  70,000

  	
   

  
	
  Annual
  Personnel Subtotal

  	
   

  	
  $

  	
  70,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Equipments:

  	
   

  	
   

  	
   

  
	
  Computer,
  software and printer

  	
   

  	
  $

  	
  5,000

  	
   

  
	
  Chromatography
  columns and lab supplies to purify IL-13-PE

  	
   

  	
  $

  	
  10,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Estimated
  Subtotal

  	
   

  	
  $

  	
  15,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Supplies:

  	
   

  	
   

  	
   

  
	
  Purchase of
  immunodeficient animals

  	
   

  	
  $

  	
  15,000

  	
   

  
	
  Tissue
  Histochemistry and Pathology & CBER Core Facility Services

  	
   

  	
  $

  	
  5,000

  	
   

  
	
  Chemicals,
  Reagents, antibodies, enzymes, test kits, cytokines

  	
   

  	
  $

  	
  20,000

  	
   

  
	
  Annual
  Supplies Subtotal

  	
   

  	
  $

  	
  40,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Travel:

  	
   

  	
   

  	
   

  
	
  Annual
  Travel Costs and Conference Fees for PI and a Fellow

  	
   

  	
  $

  	
  5,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Annual
  total for Personnel, Equipment, Supplies, and Travel

  	
   

  	
  $

  	
  130,000

  	
   

  

 

5

 

FDA’s
Contribution

 

	
  FTE:

  	
  PI Time

  	
   

  	
  15

  	
  %

  
	
   

  	
  Technician
  Time

  	
   

  	
  5

  	
  %

  
	
   

  	
  Staff
  Scientist Time

  	
   

  	
  20

  	
  %

  
	
   

  	
  Post
  Doctoral Fellow Time

  	
   

  	
  100

  	
  %

  

 

FDA Supplies:                             Some of the supplies will
be purchased with intramural budget allotted to the Puri laboratory:

 

FDA Equipment:

 

Some of the equipment needed for the collaboration are available in the
laboratory or have been purchased with funds provided by the Collaborator
during the first six years of the collaboration.

 

PI will have laboratory space to house one post-doctoral fellow and
staff scientist.

 

FDA will provide the PI, who has expertise in the field of molecular
tumor biology.  The PI will also provide
onsite supervision of the fellows, laboratory technician and staff
scientist.  The PI will direct the work
of the postdoctoral fellow by planning experiments, assuring that the fellow
performs the required work in a professional manner, evaluate and interpret the
experimental results and prepare written progress reports for the Collaborator.

 

The Collaborator agrees that the PI has broad flexibility in the use,
transfer and disbursement of funds between the resource categories described
above.  Monies not spent in a given
fiscal year will be carried over into the following year.

 

SIGNATURES
APPEAR ON THE NEXT PAGE

 

6

 

	
  FOR THE PHS:

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
    /s/ JESSE L. GOODMAN

  	
   

  	
  8/8/05

  	
   

  
	
   

  	
  Date

  	
   

  
	
  Jesse L. Goodman, M.D., M.P.H.

  	
   

  
	
  Director

  	
   

  
	
  Center for Biologics Evaluation and
  Research

  	
   

  
	
  Food and Drug Administration

  	
   

  
	
   

  	
   

  
	
  Mailing Address for Notices:

  	
   

  
	
   

  	
   

  
	
  Food and Drug Administration

  	
   

  
	
  Center for Biologics Evaluation and
  Research (HFM-544)

  	
   

  
	
  1401 Rockville Pike

  	
   

  
	
  Rockville, MD 20892

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  FOR THE COLLABORATOR:

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
    /s/ JEFFREY SHERMAN

  	
   

  	
  7/25/05

  	
   

  
	
   

  	
  Date

  	
   

  
	
  Dr. Jeff Sherman

  	
   

  
	
  Chief Medical Officer and Executive Vice
  President

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  /s/  LAWRENCE A. KENYON

  	
   

  	
  7/25/05

  	
   

  
	
   

  	
  Date

  	
   

  
	
  Larry Kenyon

  	
   

  
	
  Chief Financial Officer

  	
   

  

 

Mailing Address for Notices:

 

NeoPharm, Inc.

150 Field Drive, Suite 195

Lake Forest, IL  60045

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}]]